%0 Journal Article
%A Valldeoriola, Francesc
%A Catalán, María José
%A Escamilla-Sevilla, Francisco
%A Freire, Eric
%A Olivares, Jesús
%A Cubo, Esther
%A García, Diego Santos
%A Calopa, Matilde
%A Martínez-Martín, Pablo
%A Parra, Juan Carlos
%A Arroyo, Gloria
%A Arbelo, José Matías
%T Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
%D 2021
%@ 2373-8057
%U https://hdl.handle.net/10668/24983
%X Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson's Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, -12.8 ± 14.6; P 
%~